Cord Blood News 10.13 April 5, 2018 | |
| |
TOP STORYCord blood-derived endothelial colony-forming cells (CB-ECFCs) are subject to regulation by reactive oxygen species (ROS). Scientists specifically investigated the role of the major ROS-producing enzyme, NOX4 NADPH oxidase, which is highly expressed in CB-ECFCs, in their vasoreparative function. [Heart] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)CD133+ human umbilical cord blood mononuclear cells (HUCB-MNC) and CD133−HUCB-MNC were isolated and amplificated from umbilical cord blood, and then were exposed to different doses of radiation and subjected to a clonogenic assay. CD133+HUCB-MNC cells were more radioresistant compared with CD133−HUCB-MNC cells. [Sci Rep] Full Article Scientists found that MSCs and decellularized extracellular matrix (ECM) scaffold generated synergistic effects on promoting skeletal muscle tissue regeneration. Both MSCs and decellularized ECM scaffold could promote macrophage polarization toward the M2 phenotype and suppress macrophage polarization toward the M1 phenotype, which is widely regarded as an important promoting factor in tissue regeneration. [Stem Cell Res Ther] Full Article Intrauterine hemopoietic cell and gene therapies can potentially reduce perinatal morbidities with greater efficacy than postnatal therapy alone. The authors performed both procedures in the thalassemic HbbTh3/+ murine model. [Exp Hematol] Abstract Microvasculature-Directed Thrombopoiesis in a 3D In Vitro Marrow Microenvironment Investigators report on the development of an in vitro 3D human marrow vascular microenvironment (VME) to study hematopoietic trafficking and the release of blood cells, specifically platelets. They showed that mature megakaryocytes from aspirated marrow as well as megakaryocytes differentiated in culture from CD34+ cells can be embedded in a collagen matrix containing engineered microvessels to create a thrombopoietic VME. [PLoS One] Full Article Unrelated umbilical cord blood transplantation is an alternative to provide transplants in children with acute leukemia or myelodysplastic syndrome who lack a related donor. Scientists analyzed the impact of first-dose pharmacokinetic adapted myeloablative conditioning regimen of intravenous Busulfan on the different outcomes after transplantation. [PLoS One] Full Article | |
| |
REVIEWSCord blood is a source of transplantable hematopoietic stem cells (HSCs), but limited numbers of HSCs in single cord blood units, which may cause delayed neutrophil, platelet, and immune cell reconstitution, is a major problem for efficient transplantation. Ex vivo expansion and enhanced homing of cord blood HSCs may overcome this disadvantage and improve its long-term engraftment. Scientists discuss the role of nuclear hormone receptors signaling in human cord blood HSC engraftment. [Curr Opin Hematol] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSMagenta Therapeutics announced treatment of the first patient with an inherited metabolic disorder in a Phase II study of MGTA-456, an expanded cord blood stem cell product. MGTA-456 is a first-in-class allogeneic stem cell therapy consisting of a single umbilical cord blood unit expanded with an aryl hydrocarbon receptor antagonist then administered to a patient through a bone marrow transplant. [Magenta Therapeutics] Press Release Mesoblast Phase III Cell Therapy Trial for Chronic Low Back Pain Completes Enrollment Mesoblast Limited announced that enrollment has completed in the Phase III trial evaluating a single intra-discal injection of its proprietary allogeneic mesenchymal precursor cell product candidate MPC-06-ID in patients with chronic low back pain due to degenerative disc disease. [Mesoblast Limited] Download Press Release | |
| |
POLICY NEWSUnnecessary Exclusions Shut Patients out of Clinical Trials The FDA will hold a public meeting in Washington to discuss issues related to clinical trial eligibility criteria. Researchers, study sponsors, patients, and the general public will have an opportunity to share their experiences and tell our regulators why it’s time to revisit the guidelines. [STAT News] Editorial French Universities Cancel Subscriptions to Springer Journals French research organizations and universities have canceled their subscriptions to Springer journals, due to an impasse in fee negotiations between the publisher and Couperin.org, a national consortium representing more than 250 academic institutions in France. [The Scientist] Editorial 2018 March for Science Will Be Far More than Street Protests The March for Science has matured. It may even have outgrown its name. [ScienceInsider] Editorial EU Copyright Reforms Draw Fire from Scientists An influential committee of the European Parliament is due to vote on changes to copyright regulations in the European Union (EU), but the latest drafts of the rules have triggered a wave of criticism from open-science advocates. They say that the proposals will stifle research and scholarly communication. [Nature News] Editorial
| |
EVENTSNEW 2019 Tissue Engineering and Regenerative Medicine International Society (TERMIS) World Congress Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Hematology (Yale Cancer Center) Research Technician – Acute Myeloid Leukemia (European Molecular Biology Laboratory) Pathology Faculty Tenure Track – Leukemia and Hematopoiesis (University of Virginia) Postdoctoral Scholar – Hematology (Huntsman Cancer Institute) Postdoctoral Scholar – Clonal Hematopoiesis (Stanford University) Postdoctoral Fellow – Leukemia (Washington University) Postdoctoral Fellowship – Cell and Molecular Biology (Canadian Nuclear Laboratories) Postdoctoral Positions – Molecular Biology (Memorial Sloan Kettering Cancer Center) Postdoctoral Fellow & Scientist – Acute Myeloid Leukemia (Institute of Hematology) Postdoctoral Fellowship – Functional Genomics of Human Hematopoiesis (Boston Children’s Hospital) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|